2 active not recruiting, 1 recruiting, 1 withdrawn. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow ALL, Adult: new trials by email Literature Review of ALL, Adult trials Research Report on ALL, Adult
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy Daratumumab Injection - ALL, Adult | Phase 2 | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-01 | 2026-05-13 | |
| RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL. Blinatumomab Injection [Blincyto], Doxorubicin - ALL, Adult, Philadelphia-Negative ALL | Phase 2 | Recruiting | Chen Suning | 124 | 2024-02-05 | 2024-04-04 |
| A Study of BN104 in the Treatment of Acute Leukemia BN104 monotherapy, BN104 monotherapy - rp2d - ALL, Adult, AML, Adult | Phase 1 / Phase 2 | Active not recruiting | Institut de Recherches Internationales Servier (I.R.I.S.) | 66 | 2023-10-19 | 2026-02-25 |
| Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. Blinatumomab - ALL, Adult | Phase 2 | Active not recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 71 | 2018-06-04 | 2024-09-19 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Leukemia, Myeloid, Acute (1)
Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Leukemia (4) · Leukemia, Lymphoid (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Leukemia, Myeloid (1)
blinatumomab (2) · Doxorubicin (1) · daratumumab (1)
Chen Suning (1) · Institut de Recherches Internationales Servier (I.R.I.S.) (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1)
China (2) · Belgium (1) · Netherlands (1)
A.W. Rijneveld, Dr. (1) · Bei Liu, Dr. (1) · Dengju Li, Prof. (1) · Depei WU, Prof. (1) · Fei Li, Prof. (1) · He Huang, Prof. (1) · Hui Wei, doctor (1) · Jian Ge, Prof. (1) · Jing Lu, MD (1) · Jinhai Ren, Prof. (1) · Jun Luo, Prof. (1) · Meng LV, Dr. (1) · Mingyuan Sun, Dr. (1) · Pengcheng He, Prof. (1) · Songfu Jiang, Prof. (1)
2017 (1)